|Bid||2.43 x 100|
|Ask||2.50 x 100|
|Day's Range||2.43 - 2.49|
|52 Week Range||2.20 - 3.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Since Celldex Therapeutics Inc (NASDAQ:CLDX) released its earnings in December 2017, analyst consensus outlook seem pessimistic, as a -27.84% fall in profits is expected in the upcoming year. Though thisRead More...
Celldex (CLDX) reports narrower-than-expected loss in Q4 with sales also beating estimates. Moreover, shares rise in after-hours trading on Mar 7 following the results.
On a per-share basis, the Hampton, New Jersey-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains and non-recurring gains, were 17 cents per share. The results exceeded Wall ...
Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.
A small biotech, a Chinese tech giant, and the world's biggest coffee seller may be surprising choices to outgain Tesla. Keep reading to learn why they're on track to be better investments.
After a decades-long journey, 2018 could be the year Celldex Therapeutics transitions from a clinical-stage biotech to one with a product to sell.
Shopify has been a solid growth vehicle for investors, but these three stocks might be even better picks going forward.
Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.